vb10.neo
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 4, 2018 (NCT03548467)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05018273 | Phase 1 | Aug 31, 2021 | Genentech, Vaccibody AS |
| NCT03548467 | Phase 1/Phase 2 (Phase 2) | Apr 4, 2018 | Sponsor GmbH, Vaccibody AS |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vaccibody AS | For profit | 2 | 2 | 2 | 2018 |
| Genentech | For profit | 1 | 0 | 1 | 2021 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1